CDC25A (cell division cycle 25A)
- symbol:
- CDC25A
- locus group:
- protein-coding gene
- location:
- 3p21.31
- gene_family:
- Class III Cys-based CDC25 phosphatases
- alias symbol:
- None
- alias name:
- CDC25 homolog A (S. pombe)|M-phase…
- entrez id:
- 993
- ensembl gene id:
- ENSG00000164045
- ucsc gene id:
- uc003csh.2
- refseq accession:
- NM_001789
- hgnc_id:
- HGNC:1725
- approved reserved:
- 1992-07-31
CDC25A是一种重要的细胞周期调控基因，属于CDC25磷酸酶基因家族（包括CDC25A、CDC25B和CDC25C）。该家族基因的共同特点是编码双特异性磷酸酶，能够通过去除细胞周期蛋白依赖性激酶（CDK）上的抑制性磷酸化修饰（如CDK1和CDK2的Thr14/Tyr15位点），激活CDK-cyclin复合物，从而推动细胞周期进程（如G1/S期和G2/M期转换）。CDC25A主要在G1/S期发挥作用，其表达受转录因子E2F和 Myc调控，并通过泛素-蛋白酶体途径降解。该基因的产物通过去磷酸化CDK2促进DNA复制起始，是细胞增殖的关键调控节点。突变或异常表达会导致严重后果：功能丧失性突变可能引起细胞周期阻滞，而激活突变（如某些错义突变）或过表达会导致CDK持续活化，引发基因组不稳定和异常增殖，与乳腺癌、肝癌、结直肠癌等多种癌症密切相关。研究发现，约10%的乳腺癌患者存在CDC25A基因扩增，其过表达还可能导致p53通路失调。相反，CDC25A表达降低（如通过miRNA-21靶向抑制）会延缓细胞周期进程，在部分癌症中具有抑癌作用。此外，CDC25A与DNA损伤应答相关，辐射或化疗药物可通过CHK1激酶介导其降解，实现细胞周期检查点激活。该基因家族成员在功能上存在冗余性，但CDC25A因其在G1/S期不可替代的作用成为癌症治疗的潜在靶点，目前已有抑制剂（如BN82002）进入抗肿瘤药物研发阶段。
CDC25A is a member of the CDC25 family of phosphatases. CDC25A is required for progression from G1 to the S phase of the cell cycle. It activates the cyclin-dependent kinase CDC2 by removing two phosphate groups. CDC25A is specifically degraded in response to DNA damage, which prevents cells with chromosomal abnormalities from progressing through cell division. CDC25A is an oncogene, although its exact role in oncogenesis has not been demonstrated. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]
CDC25A是CDC25家族磷酸酶中的一员。 CDC25A需要从G1进展到细胞周期的S阶段。它由除去两个磷酸基团激活细胞周期蛋白依赖性激酶CDC2。 CDC25A响应于DNA损伤，从而防止细胞的染色体异常，从通过细胞分裂进展特异性降解。 CDC25A是一种致癌基因，尽管在肿瘤发生的确切作用还没有得到证实。已发现该基因编码不同亚型的两个转录变异体。 [由RefSeq的，2008年7月提供]
基因本体信息
CDC25A基因（以及对应的蛋白质）的细胞分布位置：
- 质膜
- 细胞质
- 细胞外
- 高尔基体
- 囊泡
- 细胞骨架
- 内质网
- 细胞核
- 内体
- 溶酶体
- 线粒体
CDC25A基因的本体（GO）信息：
| 名称 |
|---|
| 4110 Cell cycle [PATH:hsa04110] |
| 4914 Progesterone-mediated oocyte maturation [PATH:hsa04914] |
| 5206 MicroRNAs in cancer [PATH:hsa05206] |
| 名称 |
|---|
| Activation of ATR in response to replication stress |
| Cell Cycle |
| Cell Cycle Checkpoints |
| Cell Cycle, Mitotic |
| Cyclin A:Cdk2-associated events at S phase entry |
| Cyclin A/B1 associated events during G2/M transition |
| Cyclin B2 mediated events |
| Cyclin E associated events during G1/S transition |
| E2F mediated regulation of DNA replication |
| E2F-enabled inhibition of pre-replication complex formation |
| G0 and Early G1 |
| G1/S DNA Damage Checkpoints |
| G1/S Transition |
| G1/S-Specific Transcription |
| G2/M Checkpoints |
| G2/M Transition |
| Mitotic G1-G1/S phases |
| Mitotic G2-G2/M phases |
| p53-Independent DNA Damage Response |
| p53-Independent G1/S DNA damage checkpoint |
| Polo-like kinase mediated events |
| S Phase |
| Ubiquitin Mediated Degradation of Phosphorylated Cdc25A |
| 疾病名称 | 关系值 | NofPmids | NofSnps | 来源 |
| Liver carcinoma | 0.00680591 | 5 | 0 | BeFree_LHGDN |
| Mammary Neoplasms | 0.005634266 | 4 | 0 | BeFree_GAD_LHGDN |
| Lymphoma | 0.003267234 | 3 | 0 | BeFree_LHGDN |
| Malignant neoplasm of breast | 0.003257302 | 12 | 1 | BeFree |
| Breast Carcinoma | 0.002985861 | 11 | 1 | BeFree |
| Malignant neoplasm of ovary | 0.002909916 | 3 | 0 | BeFree_GAD |
| Prostatic Neoplasms | 0.00272435 | 1 | 0 | LHGDN |
| Malignant neoplasm of lung | 0.002638474 | 2 | 0 | BeFree_GAD |
| Tobacco Use Disorder | 0.002367032 | 1 | 0 | GAD |
| Animal Mammary Neoplasms | 0.002367032 | 1 | 0 | GAD |
联系方式
山东省济南市章丘区文博路2号 齐鲁师范学院 genelibs生信实验室
山东省济南市高新区舜华路750号大学科技园北区F座4单元2楼
电话： 0531-88819269
E-mail: product@genelibs.com
微信公众号
关注微信订阅号，实时查看信息，关注医学生物学动态。
版权所有 © 2025.Genelibs 济南弘晖生物技术有限公司 鲁ICP备13024435号-2
